Regarding Sipuleucel-T for use in prostate cancer, information submitted by the drug manufacturer provided better evidence on mortality. However, it is not possible to exactly estimate the extent of added benefit.
Regarding Sipuleucel-T for use in prostate cancer, information submitted by the drug manufacturer provided better evidence on mortality. However, it is not possible to exactly estimate the extent of added benefit.